

# Rui-Lan Huang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/697677/publications.pdf>

Version: 2024-02-01

56  
papers

1,951  
citations

257101

24  
h-index

253896

43  
g-index

57  
all docs

57  
docs citations

57  
times ranked

3406  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of novel DNA methylation markers in cervical cancer. <i>International Journal of Cancer</i> , 2008, 123, 161-167.	2.3	188
2	Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface. <i>Nature Communications</i> , 2018, 9, 2270.	5.8	159
3	Hypermethylation of the TGF- $\beta$ 2 target, ABCA1 is associated with poor prognosis in ovarian cancer patients. <i>Clinical Epigenetics</i> , 2015, 7, 1.	1.8	133
4	Downregulation of <i>miR-29</i> contributes to cisplatin resistance of ovarian cancer cells. <i>International Journal of Cancer</i> , 2014, 134, 542-551.	2.3	116
5	Growth Inhibition of Ovarian Tumor-Initiating Cells by Niclosamide. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1703-1712.	1.9	106
6	Quantitative DNA methylation analysis detects cervical intraepithelial neoplasms type 3 and worse. <i>Cancer</i> , 2010, 116, 4266-4274.	2.0	76
7	Methylomic Analysis Identifies Frequent DNA Methylation of Zinc Finger Protein 582 (ZNF582) in Cervical Neoplasms. <i>PLoS ONE</i> , 2012, 7, e41060.	1.1	72
8	Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer. <i>Oncotarget</i> , 2016, 7, 8993-9006.	0.8	66
9	Integrated Epigenomics Analysis Reveals a DNA Methylation Panel for Endometrial Cancer Detection Using Cervical Scrapings. <i>Clinical Cancer Research</i> , 2017, 23, 263-272.	3.2	64
10	ATL. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 201-209.	1.2	63
11	Methylomics analysis identifies epigenetically silenced genes and implies an activation of $\beta$ -catenin signaling in cervical cancer. <i>International Journal of Cancer</i> , 2014, 135, 117-127.	2.3	59
12	The role of GRHL2 and epigenetic remodeling in epithelial-mesenchymal plasticity in ovarian cancer cells. <i>Communications Biology</i> , 2019, 2, 272.	2.0	58
13	Hypomethylation signature of tumor-initiating cells predicts poor prognosis of ovarian cancer patients. <i>Human Molecular Genetics</i> , 2014, 23, 1894-1906.	1.4	56
14	Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers. <i>Epigenetics</i> , 2013, 8, 624-634.	1.3	51
15	Idiopathic Low Ovarian Reserve Is Associated with More Frequent Positive Thyroid Peroxidase Antibodies. <i>Thyroid</i> , 2017, 27, 1194-1200.	2.4	46
16	Global methylation silencing of clustered <i>protocadherin</i> genes in cervical cancer: serving as diagnostic markers comparable to HPV. <i>Cancer Medicine</i> , 2015, 4, 43-55.	1.3	40
17	Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer. <i>PLoS ONE</i> , 2017, 12, e0182166.	1.1	39
18	Genome-wide DNA methylation analysis reveals estrogen-mediated epigenetic repression of metallothionein-1 gene cluster in breast cancer. <i>Clinical Epigenetics</i> , 2015, 7, 13.	1.8	38

#	ARTICLE	IF	CITATIONS
19	Promoter Hypomethylation of EpCAM-Regulated <i>Bone Morphogenetic Protein</i> Gene Family in Recurrent Endometrial Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 6272-6285.	3.2	37
20	TET1 promotes 5hmC-dependent stemness, and inhibits a 5hmC-independent epithelial-mesenchymal transition, in cervical precancerous lesions. <i>Cancer Letters</i> , 2019, 450, 53-62.	3.2	33
21	GATA3 as a master regulator and therapeutic target in ovarian high-grade serous carcinoma stem cells. <i>International Journal of Cancer</i> , 2018, 143, 3106-3119.	2.3	31
22	DNA methylation as a biomarker for the detection of hidden carcinoma in endometrial atypical hyperplasia. <i>Gynecologic Oncology</i> , 2014, 135, 552-559.	0.6	28
23	Combined genetic mutations and DNA-methylated genes as biomarkers for endometrial cancer detection from cervical scrapings. <i>Clinical Epigenetics</i> , 2019, 11, 170.	1.8	28
24	E2F6 functions as a competing endogenous RNA, and transcriptional repressor, to promote ovarian cancer stemness. <i>Cancer Science</i> , 2019, 110, 1085-1095.	1.7	27
25	Triage of high-risk human papillomavirus-positive women by methylated POU4F3. <i>Clinical Epigenetics</i> , 2015, 7, 85.	1.8	26
26	An epigenetic signature of adhesion molecules predicts poor prognosis of ovarian cancer patients. <i>Oncotarget</i> , 2017, 8, 53432-53449.	0.8	25
27	Concordance analysis of methylation biomarkers detection in self-collected and physician-collected samples in cervical neoplasm. <i>BMC Cancer</i> , 2015, 15, 418.	1.1	24
28	Paired Box-1 (PAX1) Activates Multiple Phosphatases and Inhibits Kinase Cascades in Cervical Cancer. <i>Scientific Reports</i> , 2019, 9, 9195.	1.6	24
29	TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2 $\beta$ as a therapeutic target. <i>Journal of Pathology</i> , 2019, 248, 363-376.	2.1	23
30	Ovarian cancer detection by DNA methylation in cervical scrapings. <i>Clinical Epigenetics</i> , 2019, 11, 166.	1.8	22
31	Loss of discoidin domain receptor 1 (DDR1) via CpG methylation during EMT in epithelial ovarian cancer. <i>Gene</i> , 2017, 635, 9-15.	1.0	20
32	Ovarian cancer stem-like cells with induced translineage-differentiation capacity and are suppressed by alkaline phosphatase inhibitor. <i>Oncotarget</i> , 2013, 4, 2366-2382.	0.8	20
33	Genotype-specific methylation of HPV in cervical intraepithelial neoplasia. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e56.	1.0	19
34	Multiple epithelial and nonepithelial tumors in hereditary nonpolyposis colorectal cancer: characterization of germline and somatic mutations of the MSH2 gene and heterogeneity of replication error phenotypes. <i>Cancer Genetics and Cytogenetics</i> , 2004, 153, 108-114.	1.0	17
35	Serum cytokeratin-19 fragment (Cyfra 21-1) is a prognostic indicator for epithelial ovarian cancer. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2014, 53, 30-34.	0.5	13
36	Distinct methylation profile of mucinous ovarian carcinoma reveals susceptibility to proteasome inhibitors. <i>International Journal of Cancer</i> , 2018, 143, 355-367.	2.3	12

#	ARTICLE	IF	CITATIONS
37	Epigenetic loss of heparan sulfate 3-sulfation sensitizes ovarian carcinoma to oncogenic signals and predicts prognosis. <i>International Journal of Cancer</i> , 2018, 143, 1943-1953.	2.3	11
38	Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report. <i>Journal of Ovarian Research</i> , 2020, 13, 143.	1.3	9
39	Methylomics of nitroxidative stress on precancerous cells reveals DNA methylation alteration at the transition from in situ to invasive cervical cancer. <i>Oncotarget</i> , 2017, 8, 65281-65291.	0.8	9
40	Presacral teratoma in a Curarrino syndrome woman with an unreported insertion in MNX1 gene. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2011, 50, 512-514.	0.5	8
41	Squamous cell carcinoma arising from an ovarian teratoma related to human papillomavirus infection: Using a PCR-based reverse-blot assay. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2011, 50, 543-545.	0.5	7
42	Platelet-Derived Growth Factor in the Ovarian Follicle Attracts the Stromal Cells of the Fallopian Tube Fimbriae. <i>PLoS ONE</i> , 2016, 11, e0158266.	1.1	7
43	Transition from multiport to single-site surgery: A single institution experience in robotic supracervical hysterectomy for benign gynecological diseases. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2019, 58, 514-519.	0.5	7
44	MeDIP-on-Chip for Methylation Profiling. <i>Methods in Molecular Biology</i> , 2015, 1249, 281-290.	0.4	7
45	NKX6-1 mediates cancer stem-like properties and regulates sonic hedgehog signaling in leiomyosarcoma. <i>Journal of Biomedical Science</i> , 2021, 28, 32.	2.6	6
46	The cytokine-cosmc signaling axis upregulates the tumor-associated carbohydrate antigen Tn. <i>Oncotarget</i> , 2016, 7, 61930-61944.	0.8	4
47	Paired boxed gene 1 expression: A single potential biomarker for differentiating endometrial lesions associated with favorable outcomes in patients with endometrial carcinoma. <i>Journal of Obstetrics and Gynaecology Research</i> , 2016, 42, 1159-1167.	0.6	3
48	Genome-wide analysis of cervical secretions obtained during embryo transfer reveals the association between deoxyribonucleic acid methylation and pregnancy outcomes. <i>F&amp;S Science</i> , 2022, 3, 74-83.	0.5	3
49	Epigenomic Profiling of Epithelial Ovarian Cancer Stem-Cell Differentiation Reveals GPD1 Associated Immune Suppressive Microenvironment and Poor Prognosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5120.	1.8	3
50	Epigenomic Analysis Reveals the KCNK9 Potassium Channel as a Potential Therapeutic Target for Adenomyosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5973.	1.8	3
51	Novel germline and somatic mutations of the MSH2 gene in hereditary non-polyposis colorectal cancer. <i>Clinical Genetics</i> , 2007, 71, 190-192.	1.0	2
52	BHLHE22 Expression Is Associated with a Proinflammatory Immune Microenvironment and Confers a Favorable Prognosis in Endometrial Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7158.	1.8	2
53	Abstract 3433: Disruption of TGF- $\beta$ signaling induces demethylation of E-cadherin promoter and reverses mesenchymal phenotype in ovarian cancer. <i>Cancer Research</i> , 2011, 71, 3433-3433.	0.4	1
54	Abstract 1110: Effect of miR-29 on cisplatin sensitivity of ovarian cancer cells. , 2012, , .		0

#	ARTICLE	IF	CITATIONS
55	Abstract 1128: TET1-mediated epigenetic reprogramming switches metabolism and promotes malignant phenotypes of ovarian cancer. , 2015, , .		0
56	Epigenetic biomarker and drug development in gynecological cancers. , 2022, , 223-255.		0